Licciardone John C, Gatchel Robert J, Phillips Nicole, Aryal Subhash
Department of Family Medicine, University of North Texas Health Science Center, Fort Worth, TX, USA,
Department of Psychology, College of Science, University of Texas at Arlington, Arlington, TX, USA.
J Pain Res. 2018 Sep 6;11:1751-1760. doi: 10.2147/JPR.S169275. eCollection 2018.
Low back pain is the leading cause of disability worldwide. Nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended as the first-line pharmacologic therapy for subacute or chronic low back pain, with opioids reserved for patients who fail on NSAIDs. , , and genes have variants that place patients using analgesics at risk for adverse events. However, precision medicine based on pharmacogenetically informed prescribing is becoming more feasible as genotyping costs decline. This study aims to compare opioids vs NSAIDs in treating adults with subacute or chronic low back pain under the alternative models of usual care and precision medicine.
An observational cohort study within the Pain Registry for Epidemiological, Clinical, and Interventional Studies and Innovation (PRECISION) will be used to simulate a randomized controlled trial. Patients using opioids and NSAIDs will be optimally matched at baseline using propensity scores. A saliva sample will also be collected to determine patient genotypes for drug metabolism based on (single-gene model) and , , and (multigene model). Prescribing that is concordant with pharmacogenetically informed care under these models will be considered "low risk", whereas discordant prescribing will be considered "high risk". Primary outcomes will be assessed over 6 months using a Numerical Rating Scale for pain, the Roland-Morris Disability Questionnaire, and the Drug Adverse Events Index. Secondary outcomes will be assessed using quality-of-life measures. An estimated 600 patients will be enrolled to acquire at least 400 patients after attrition and allowing for unmatched patients. This will achieve a statistical power of at least 80% in detecting the effect sizes ranging from 0.35 (small-medium effect) to 0.69 (medium-large effect).
This PRECISION Pain Research Registry study builds on the concepts espoused in the Precision Medicine Initiative and addresses long-term goals established by the National Institutes of Health by assessing how precision medicine may prevent and treat chronic pain.
腰痛是全球致残的主要原因。非甾体抗炎药(NSAIDs)被推荐作为亚急性或慢性腰痛的一线药物治疗,阿片类药物则用于NSAIDs治疗失败的患者。 、 和 基因存在变异,使用镇痛药的患者有发生不良事件的风险。然而,随着基因分型成本的下降,基于药物基因组学指导处方的精准医学变得越来越可行。本研究旨在比较在常规护理和精准医学的替代模式下,阿片类药物与NSAIDs治疗亚急性或慢性腰痛成人患者的疗效。
将在疼痛流行病学、临床、干预研究与创新注册库(PRECISION)内进行一项观察性队列研究,以模拟随机对照试验。使用阿片类药物和NSAIDs的患者将在基线时使用倾向评分进行最佳匹配。还将收集唾液样本,以根据 (单基因模型)和 、 和 (多基因模型)确定患者的药物代谢基因型。在这些模型下,与药物基因组学指导护理一致的处方将被视为“低风险”,而不一致的处方将被视为“高风险”。主要结局将在6个月内使用疼痛数字评定量表、罗兰-莫里斯残疾问卷和药物不良事件指数进行评估。次要结局将使用生活质量指标进行评估。预计将招募600名患者,在剔除和考虑不匹配患者后至少获得400名患者。这将在检测效应大小范围从0.35(中小效应)到0.69(中大型效应)时实现至少80%的统计效力。
这项PRECISION疼痛研究注册库研究基于精准医学计划中所倡导的概念,并通过评估精准医学如何预防和治疗慢性疼痛来实现美国国立卫生研究院确立的长期目标。